Cardiovascular Effects of Fluoxetine in Depressed Patients With Heart Disease
作者： Steven P. Roose , Alexander H. Glassman , Evelyn Attia , Sally Woodring , Elsa-Grace V. Giardina
关键词:
摘要: OBJECTIVE: The purpose of this study was to determine the cardiovascular effects fluoxetine in depressed patients with cardiac disease. METHOD: Twenty-seven (26% whom were female and whose average age 73 years) who had congestive heart failure, conduction disease, and/or ventricular arrhythmia studied an open medication trial fluoxetine, up 60 mg/day, for 7 weeks. main outcome measures rate rhythm measured by 24-hour ECG recordings, ejection fraction determined radionuclide angiography, intervals, blood pressure. Baseline values compared those at weeks 2 treatment. In comparable patients, these same baseline after 3 treatment a tricyclic antidepressant, nortriptyline, also examined. RESULTS: Fluoxetine induced statistically significant 6% decrease rate, 2% increase supine systolic pressure, 7% ...
sci-hub.se 参考文章(23)
Wernicke Jf, The side effect profile and safety of fluoxetine. The Journal of Clinical Psychiatry. ,vol. 46, pp. 59- 67 ,(1985)
G. W. Dalack, A. H. Glassman, S. Woodring, E. G V Giardina, B. T. Walsh, S. P. Roose, Is doxepin a safer tricyclic for the heart The Journal of Clinical Psychiatry. ,vol. 52, pp. 338- 341 ,(1991)
Cardiac Arrhythmia Suppression Trial II Investigators*, None, EFFECT OF THE ANTIARRHYTHMIC AGENT MORICIZINE ON SURVIVAL AFTER MYOCARDIAL-INFARCTION The New England Journal of Medicine. ,vol. 327, ,(1992)
Glenn L. Cooper, The safety of fluoxetine--an update. The British journal of psychiatry. Supplement. ,vol. 153, pp. 77- 86 ,(1988) , 10.1192/S000712500029733X
S E Coplen, E M Antman, J A Berlin, P Hewitt, T C Chalmers, Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. ,vol. 82, pp. 1106- 1116 ,(1990) , 10.1161/01.CIR.82.4.1106
J Morganroth, J E Goin, Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis. Circulation. ,vol. 84, pp. 1977- 1983 ,(1991) , 10.1161/01.CIR.84.5.1977
STEVEN P. ROOSE, ALEXANDER H. GLASSMAN, ELSA G.V. GIARDINA, LYNNE L. JOHNSON, B. TIMOTHY WALSH, J. THOMAS BIGGER, Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. Journal of Clinical Psychopharmacology. ,vol. 7, pp. 247- 251 ,(1987) , 10.1097/00004714-198708000-00007
JW Upward, JG Edwards, A Goldie, DG Waller, Comparative effects of fluoxetine and amitriptyline on cardiac function. British Journal of Clinical Pharmacology. ,vol. 26, pp. 399- 402 ,(1988) , 10.1111/J.1365-2125.1988.TB03397.X
Debra S. Echt, Philip R. Liebson, L. Brent Mitchell, Robert W. Peters, Dulce Obias-Manno, Allan H. Barker, Daniel Arensberg, Andrea Baker, Lawrence Friedman, H. Leon Greene, Melissa L. Huther, David W. Richardson, Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo New England Journal of Medicine. ,vol. 324, pp. 781- 788 ,(1991) , 10.1056/NEJM199103213241201
J.Thomas Bigger, Implications of the cardiac arrhythmia suppression trial for antiarrhythmic drug treatment The American Journal of Cardiology. ,vol. 65, pp. 3- 10 ,(1990) , 10.1016/0002-9149(90)91410-8